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Context: Fibroblast growth factor (FGF) 8 is important for GnRH neuronal development with
human mutations resulting in Kallmann syndrome. Murine data suggest a role for Fgf8 in hypo-
thalamo-pituitary development; however, its role in the etiology of wider hypothalamo-pituitary
dysfunction in humans is unknown.
Objective: The objective of this studywas to screen for FGF8mutations in patientswith septo-optic
dysplasia (n  374) or holoprosencephaly (HPE)/midline clefts (n  47).
Methods: FGF8was analyzed by PCR anddirect sequencing. Ethnicallymatched controlswere then
screened formutated alleles (n 480–686). Localization of Fgf8/FGF8 expressionwas analyzed by
in situ hybridization in developing murine and human embryos. Finally, Fgf8 hypomorphic mice
(Fgf8loxPNeo/) were analyzed for the presence of forebrain and hypothalamo-pituitary defects.
Results: A homozygous p.R189H mutation was identified in a female patient of consanguineous
parentage with semilobar HPE, diabetes insipidus, and TSH and ACTH insufficiency. Second, a
heterozygousp.Q216Emutationwas identified ina femalepatientwithanabsent corpus callosum,
hypoplastic optic nerves, andMoebius syndrome. FGF8was expressed in the ventral diencephalon
and anterior commissural plate but not in Rathke’s pouch, strongly suggesting early onset hypo-
thalamic and corpus callosal defects in these patients. This was consolidated by significantly re-
duced vasopressin and oxytocin staining neurons in the hypothalamus of Fgf8 hypomorphic mice
compared with controls along with variable hypothalamo-pituitary defects and HPE.
Conclusion:We implicate FGF8 in the etiology of recessive HPE and potentially septo-optic dysplasia/
Moebius syndrome for the first time to our knowledge. Furthermore, FGF8 is important for the de-
velopment of the ventral diencephalon, hypothalamus, and pituitary. (J Clin Endocrinol Metab 96:
E1709–E1718, 2011)
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Complexmidline defects of the forebrain in humans arerare but may be associated with hypopituitarism,
which in turn may lead to significant morbidity and mor-
tality. They span a wide spectrum of phenotypes ranging
from those which are incompatible with life, to holopros-
encephaly (HPE) and cleft palate and septo-optic dyspla-
sia (SOD).
SOD is a highly heterogeneous condition which, al-
though usually sporadic and inclusive of possible environ-
mental (including drug and alcohol induced) pathologies,
has also been identified in a number of familial cases in-
volving mutations in an increasing number of early devel-
opmental transcription factors includingHESX1, SOX2,
SOX3, and OTX2 (1–5). These genes are expressed in
regions that determine the formation of forebrain and re-
lated midline structures such as the hypothalamus and
pituitary (6). Consequently, SOD is characterized by vari-
able phenotypes including midline telencephalic abnor-
malities, optic nerve hypoplasia, and pituitary hypoplasia
with variable pituitary hormone deficiencies (7, 8).
HPE is etiologically heterogeneous but is the most fre-
quent developmental forebrain anomaly in humans, with
an incidence in liveborns of approximately one in 10,000–
20,000 and in conceptuses as high as one in 250 (9). It
results from varying degrees of incomplete cleavage of the
prosencephalon into the cerebral hemispheres and ventri-
cles. In addition, failure of the frontal and parietal lobes to
divide posteriorly results in an absent corpus callosum.
Facial features associated with HPE include cyclopia,
anophthalmia,midface hypoplasia, hypotelorism, cleft lip
and/or palate, and a single central incisor (10).
Recent studies have implicated a number of heterozy-
gous genetic missense mutations and deletions in the eti-
ology of HPE; cytogenetically visible abnormalities are
estimated tobepresent in25%ofHPEpatients (11).These
in turn have led to the identification of a number of caus-
ative genes, including SHH,ZIC2, SIX3, andTGIF1with
subsequent identification of mutated genes in associated
pathways including PTCH1, GLI2, DISP1, TDGF1,
GAS1,EYA4, and FOXH1 (12–14). However, mutations
have been identified in only 17% of cytogenetically nor-
mal children with HPE. In recent studies, submicroscopic
deletions of a number of loci believed to be implicated in
HPE were identified in a number of individuals with HPE
(15), suggesting that a number of genetic mutations re-
main to be described.
Although not previously related to hypopituitarism,
Kallmann syndrome is classically defined as the associa-
tion of hypogonadotrophic hypogonadism with anosmia
due to hypoplasia of the olfactory bulbs (16). However,
the condition is genetically and clinically heterogeneous
and may be associated with craniofacial defects such as
Moebius syndrome, which is characterized by malforma-
tion of the sixth and seventh facial nerves (17, 18). One of
the genetic pathways involved in Kallmann syndrome is
the ubiquitously expressed fibroblast growth factor (FGF)
family of signaling molecules and its receptors (19). Loss-
of-function mutations in human FGF8 and FGFR1 have
been implicated in this condition, and these factors po-
tentially link the disorder to hypopituitarism through the
requirement of Fgf8 tomaintain anterior pituitary cellular
proliferation via Lhx3 in mice (20, 21). Recently a puta-
tive role for FGF8 in two patients with HPE has been
postulated upon the identification of two heterozygous
mutations: 1) a 138-kb deletion at 10q24.3 encompassing
FGF8 as well as a number of other genes (15), and 2) a
p.T229M substitution associated with incomplete pen-
etrance, which has previously been described in associa-
tionwith isolatedhypogonadotrophic hypogonadism (16,
22). Although the latter patient manifested diabetes insip-
idus, therewasnoother evidenceof endocrinedysfunction
in the two pedigrees.
We hypothesized that FGF8 may be essential for the
development of the forebrain and pituitary gland in hu-
mans andmouse and that mutations in this genemay con-
tribute to the etiology of disorders such as SOD andHPE.
Patients and Methods
Patients
A total of 421 patients with congenital hypopituitarism and
midline craniofacial/forebrain defects (SOD or HPE) were re-
cruited between 1998 and 2010; 167 patients (39.7%) were re-
cruited at the London Centre for Pediatric Endocrinology based
atGreatOrmond StreetHospital forChildren and theUniversity
College London Hospital, and 157 (37.3%) were referred from
national and 97 (23%) from international centers. Ethical com-
mittee approval was obtained from the University College Lon-
don Institute of Child Health/Great Ormond Street Hospital for
Children Joint Research Ethics Committee, and informed writ-
ten consent was obtained from patients and/or parents. Of the
421 patients screened (male to female ratio 1.1:1), 88.8% (n 
374)hadSODand its variants,whereas11.2%(n47)hadHPE
or midline clefts.
Mutation analysis
The coding region of human FGF8 (NM_033163) was am-
plified by PCR on an Eppendorf Thermocycler (Netheler, Ger-
many) over 35 cycles with primers designed using the Primer3
program (available at http://frodo.wi.mit.edu/primer3) flanking
each of the coding regions, including the four alternative splice
variants of exon 1 (Fig. 1). PCR parameters are available on
request. For direct sequencing formutations, PCRproductswere
treated withMicroClean reagent (Web Scientific, Cheshire, UK;
catalog no. 2MCL-10) according tomanufacturer’s instructions
and then sequenced using BigDye version 1.1 sequencing chem-
istry (Applied Biosystems, Warrington, UK) and analyzed on a
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3730X1DNAanalyzer (AppliedBiosystems/Hitachi, Tokyo, Ja-
pan; catalog no. 625-0020). Upon discovering FGF8mutations,
480–686 controls were screened at the same allele to provide
comparisons.
In situ hybridization and hypomorphic mice
In situhybridizationwasperformedonparaffin sections from
mouse and human embryos as previously described (24). Sec-
tions of human embryos were obtained from the Human Devel-
opmentalBiologyResource (UniversityCollegeLondon Institute
of Child Health, London, UK). The human FGF8 and FGFR1
probes were obtained from the Source BioScience LifeSciences
(http://www.lifesci.ences.sourcebioscience.com/). The Fgf8 hy-
pomorphic mouse embryos (Fgf8loxPNeo/) were obtained by
crossing the Fgf8/ with Fgf8loxPNeo/ line as has previously
been described (25).
Immunohistochemistry and
quantification of hypothalamic arginine
vasopressin (AVP)-expressing nuclei
Brains from wild-type, heterozygote, and ho-
mozygote Fgf8 hypomorphic mouse embryos
(Fgf8loxPNeo/) were collected at postnatal day (PN)
0 and processed for immunohistochemistry on
50-mfrozen sections. Sectionswere taken from the
preoptic area to the mamillary bodies, and neurons
were stained for AVP using a rabbit anti-AVP anti-
body (Millipore, Billerica, CA; catalog no. AB1565)
for 48 h at 4 C. These were then sequentially incu-
batedwith a biotinylated donkey antirabbit second-
ary antibody (1:500; Jackson ImmunoResearch,
West Grove, PA) and the avidin-biotin complex
(Vector Laboratories, Burlingame, CA). Immuno-
reactivity was visualized with diaminobenzidine as
the chromagen before counterstaining with methyl
green.
Quantification of AVP-immunoreactive para-
ventricular nuclei (PVN) and suprachiasmatic
nuclei (SCN) were conducted as recently de-
scribed (26).
Statistical analysis
Treatments presented (see Fig. 4T) were com-
pared with controls by ANOVA followed by Stu-
dent Newman-Keuls test. P  0.05 was used to
determine whether results were statistically sig-
nificant. All statistics were performed using Sig-
maStat version 3.5 (Systat Software, Inc., San
Jose, CA).
Results
Mutation analysis
After direct sequencing of 421 patients, two unre-
lated female patients were detected with novel muta-
tions in exon 3 of FGF8. These included: 1) a homozy-
gous mutation, c.566GA, resulting in the substitution
of arginine by histidine (p.R189H) (patient 1) and 2) a
heterozygous mutation, c.646CG, resulting in the
substitution of glutamine by glutamic acid (p.Q216E)
(patient 2). The clinical characteristics of both patients
FIG. 1. Structure of FGF8 isoforms. Schematic representation of the four FGF8
isoforms (A, B, E, and F) resulting from alternative splicing of exons 1C and 1D. The
lettering refers to the specific FGF8 isoform. Exons are designated inside the
rectangles and numbers above each exon-exon boundary indicate the amino acid
position in the FGF8f isoform. The core region of the protein is predominantly made
up of exons 2 and 3, which is conserved between isoforms. Previously identified
mutations are indicated by arrows and numbered according to the FGF8f protein
isoform, with the two novel mutations presented within this paper in blue type. Note
that the asterisk denotes homozygous mutations. [Adapted from J. Falardeau et al.:
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in
humans and mice. J Clin Invest 118:2822–2831, 2008 (16), with permission.
© American Society for clinical Investigation; and E. Trarbach et al.: Nonsense
mutations in FGF8 gene causing different degrees of human gonadotropin-releasing
deficiency. J Clin Endocrinol Metab 95:3491–3496, 2010 (23), with permission.
© The Endocrine Society.
TABLE 1. Clinical characteristics of affected patients with FGF8 mutations
Patient
no. Mutation Position Sex Hypothalamo-pituitary MRI Other
1 Homozygous c.566GA, p.R189H F DI, ACTHI, evolving TSHD,
PRLD
Semilobar HPE,
bulky AP
DD, high arched palate,
maxillary hypoplasia
2 Heterozygous c.646CG, p.Q216E F Borderline GH response
to provocation
Agenesis of CC, optic
nerve hypoplasia,
normal pituitary
Moebius syndrome,
microcephaly, DD,
spastic diplegia
DI, Diabetes insipidus; ACTHI, ACTH insufficiency; TSHD, TSH deficiency; PRLD, prolactin deficiency; CC, corpus callosum; DD, developmental
delay; AP, anterior pituitary; F, female.
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are presented in Table 1. None of 480 Caucasian con-
trols screened exhibited either of the mutations. In ad-
dition, for patient 1, who was of Pakistani origin,
screening a further 206 ethnically matched controls re-
vealed no mutations. Neither patient identified with an
FGF8 mutation had mutations in FGFR1, KAL1,
PROK2, PROKR2, HESX1, or SHH.
Patient 1
A female patient from a consanguineous family of Pak-
istani origin had been diagnosed antenatally with holo-
prosencephaly and absent corpus callosum; at birth she
was noted tohavemicrocephaly,micrognathia, and ahigh
arched palate. She presented at the age of 7 wk with sei-
zures and hypernatremia and was admitted to intensive
care. Although her critical condition did not allow for
extensive endocrine investigations, she was diagnosed
with diabetes insipidus and ACTH insufficiency and has
been treated with desmopressin and hydrocortisone. A
brainmagnetic resonance imaging (MRI) confirmed semi-
lobar holoprosencephaly with separation of the cerebral
hemispheres anteriorly and failure of separation of the
basal ganglia structures and the thalami from each other
and across the midline. The corpus callosum was absent,
and the hypothalamus was abnormal. The anterior pitu-
itary gland was noted to be bulky, and the posterior pi-
tuitary was identified at the normal location (Fig. 2F).
A glucagon stimulation test performed at the age of 5.5
yr [height 107.6 cm (0.6 SD score [SDS]), weight 16.6 kg
(0.9SDS)] showedanormalGHresponse (peakGH29.1
g/liter) with normal IGF-I (148 ng/ml; normal range 52–
297 ng/ml) and IGF binding protein-3 (3.19mg/liter; nor-
mal range 1.3–5.6 mg/liter), but she gradually developed
TSHdeficiency as shown by persistently low free T4 (FT4)
concentrations, with a progressive reduction in prolactin
concentrations (Table 2).
FIG. 2. Two novel mutations associated with recessive HPE and SOD. A and B, A total of 421 patients with hypopituitarism phenotypes ranging
from HPE to SOD were screened for mutations in FGF8 by direct sequencing. A female patient with HPE exhibited a novel homozygous mutation
at position c.566, resulting in a p.R189H substitution (A, arrow) in a highly conserved residue in all vertebrates analyzed (B). C and D, A second
female patient with SOD and Moebius syndrome exhibited a novel heterozygous mutation at position c.646, leading to a p.Q216E substitution (C,
arrow) in a highly conserved amino acid among mammals (D). E, Sagittal MRI scan of our SOD/Moebius syndrome patient (Q216E), demonstrating
an absent corpus callosum (asterisk) but otherwise normal anterior pituitary (AP) and posterior pituitary (PP) glands. F, Sagittal and coronal MRI
scans of a normal control subject and our HPE (p.R189H) patient. The latter presented with an absent corpus callosum (asterisk) and an enlarged
anterior pituitary (AP). Failure of the brain to divide into its cerebral hemispheres in the patient is apparent in the coronal sections with a clearer
view of the absent corpus callosum in the far right image.
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Genetic screening revealed that she was homozygous
for a novel FGF8 mutation (c.566GA, p.R189H) in-
volving ahighly conserved regionof the gene (Fig. 2,Aand
B). Both parents were heterozygous and had a normal
phenotype with no history of delayed puberty or subfer-
tility and a reported normal sense of smell.
Patient 2
A Caucasian female patient with SOD and agenesis of
corpus callosum presented at the age of 6 yr for investi-
gation of profound growth deceleration with a height of
99.2 cm (2.7 SDS) and a weight of 15.8 kg (1.9 SDS).
She was born to unrelated parents, and in addition to
SOD, she had microcephaly, global developmental delay
with evolving spastic diplegia, and Moebius syndrome.
Endocrine investigations revealed a low normal concen-
tration of IGF-I [107 g/liter (normal range: 53–302g/
liter)] with borderline peakGH responses to glucagon and
clonidine stimulation (5.13 and 5 g/liter, respectively),
normal thyroid function, and an adequate peak cortisol in
response to both glucagon (16.1g/dl) and synacthen (30
g/dl) stimulation. Brain MRI revealed an absent corpus
callosum and hypoplastic optic nerves with no structural
abnormality of the pituitary gland (Fig. 2E). She had no
evidence of anymidline cleft, nor did shemanifest diabetes
insipidus. The patient is currently too young to test for
olfactory dysfunction.
The patient was heterozygous for a novel FGF8muta-
tion (c.646CG,p.Q216E) (Fig. 2C) inahighly conserved
region of the gene across multiple species (Fig. 2D),
whereas her unaffected mother was a carrier.
Expression analysis of FGF8 and FGFR1 in the
developing human embryo
To understand the role of FGF8 and FGFR1 in human
embryonic development and to bring insights into the
pathogenesis of the phenotypes observed in patients har-
boringmutations in these genes, we performed expression
analysis of FGF8 and FGFR1 in human embryos.
In situ hybridization analyses on early-staged human
embryos, Carnegie stage (CS) 16, revealed FGF8 mRNA
transcripts in the midline commissural plate of the devel-
oping telencephalon and telencephalic/diencephalic bor-
der and in the ventral diencephalon, but no expressionwas
observed in Rathke’s pouch (the primordium of the ante-
rior pituitary) (Fig. 3A). In mouse, expression of Fgf8 in
the ventral diencephalon is essential for Rathke’s pouch
induction and growth (21, 27, 28). In agreement with this
notion, expression of FGFR1, which is the main receptor
mediating FGF8 signaling, was detected in Rathke’s
pouch (Fig. 3, B andD) and in abroader domainwithin the
ventral diencephalon (Fig. 3B). At CS 22, FGFR1 tran-
scripts were present in the neuroepithelium of the devel-
oping brain and in Rathke’s pouch (Fig. 3E). FGF8 and
FGFR1 expression patterns in the human embryo parallel
that of the mouse, suggesting a conserved function for
FGF8 and FGFR1 in the development of these structures.
Hypothalamic and pituitary defects in mouse
embryos carrying a hypomorphic Fgf8 allele
Mouse embryos carrying a hypomorphic allele of Fgf8
(Fgf8-loxPNeo) over a null allele (Fgf8loxPNeo/) show se-
vere defects in brain morphogenesis, including midbrain
defects, absence of olfactory bulbs and optic chiasm, and
HPE with an abnormal corpus callosum [Meyers et al.
(25); Storm et al. (29)]. To further understand the patho-
genesis of the defects observed in the patients carrying
FGF8mutations, we analyzed by in situ hybridization the
differentiationof hormone-producing cells in the pituitary
gland and the integrity of the neuroendocrine hypothala-
mus in Fgf8 hypomorphic mouse embryos. In addition to
HPE, which was observed in two of six mutants analyzed,
Fgf8loxPNeo/ embryos showed severe abnormalities in the
pituitary gland and endocrine hypothalamus (Fig. 4). At
17.5 d postcoitum,weobserved twodifferent phenotypes:
1) a severe one, characterized by the substantial reduction
of anterior pituitary tissue and absence of posterior lobe
TABLE 2. Serial endocrine evaluation of patient 1 (p.R189H)
Age
Cortisol
(g/dl)
Peak GH
(g/liter)
(NR >6.7
g/liter)
FT4
(ng/dl) FT4 NR
TSH
(mU/liter)
(NR <6mU/
liter)
Basal PRL
(g/liter)
PRL NR
(g/liter)
Basal LH
(IU/liter)
Basal FSH
(IU/liter)
8 wk 1–5.3 on profile ND 1.63 1.09–1.78 7.4 70.5 4.9–67 0.7 2.7 IU/liter
21 months ND ND 1.24 1.09–1.78 3.6 ND ND ND
4 yr ND ND 0.96 0.93–1.71 1.4 6.79 3.1–11.1 ND ND
5.5 yr 18 (peak GST
on hydrocortisone)
29.1 1.00 0.84–1.47 1.1 3.34 3.1–11.1 0.2 0.8
6.5 yr ND ND 0.98 1.00–1.65 0.88 ND ND ND
7 yr ND ND 0.79 0.84–1.47 1.2
GST, Glucagon stimulation test; PRL, prolactin; ND, not done; NR, normal range.
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(two of six embryos analyzed) (Fig. 4, B, E, H, K, and N);
and 2) a mild phenotype, in which the pituitary gland was
morphologicallymore comparablewith the controls (four
of six embryos analyzed) (Fig. 4, C, F, I, L, andO).Despite
thesemorphological abnormalities, the only defects in ter-
minal differentiation of the hormone-producing cellswere
observed in those secreting LH.
Next, we studied the integrity of the endocrine hypo-
thalamus in the Fgf8 hypomorph embryos. A marked re-
duction of AVP and oxytocin (OT) neurons was observed
in the supraoptic (SON), SCN, and PVN nuclei in these
mutant embryos relative to the controls (Fig. 4, P–S).
Quantification of AVP-immunoreactive neurons on PN0
confirmed a significant (P  0.002) loss of these neurons
in the SCN and PVN of FGF8 hypomorphs (Fig. 4T).
Together these expression analyses in mouse embryos
highlight an essential role for FGF8 signaling in the for-
mation of the hypothalamic-pituitary axis and provide
insights into the pathogenesis of the brain and endocrine
defects observed in patients carrying mutations in FGF8
and FGFR1.
Discussion
Novel homozygous mutation in FGF8 in a female
with holoprosencephaly
We have identified a novel homozygous mutation,
c.566GA (p.R189H), in exon 3 of FGF8, which resulted
in an arginine substitution for histidine in the C-terminal
region of the protein, in a patient with
semilobar HPE associated with an ab-
sent corpus callosum and a bulky ante-
rior pituitary on MRI. The parents of
our proband are both unaffected carri-
ers of themutationandare first cousins.
The recessive nature of this mutation,
which occurs at a highly conserved res-
idue, and its absence in 686 controls,
suggests thatFGF8 is critical fornormal
forebrain development, as indicated in
a murine model carrying a hypomor-
phic Fgf8 allele (25, 29, 30).
Theaffectedregionoftheproteiniscon-
served across all isoforms and the variably
penetrant loss-of-function heterozygous
T229M mutation, which lies in the same
region, has previously been associated
with hypogonadotrophic hypogonadism
and HPE (16, 22). However, in vitro li-
gand receptor binding assays using bac-
teriological recombinantproteins appear
to indicate that this FGF8 region may
not be important for receptor binding (30). This sug-
gests that FGF8 activity in vivo may require posttrans-
lational modifications, which were absent in the recom-
binant proteins used in the previous study, but
important for other aspects of FGF8 biology such as
intracellular transport, diffusion, or protein half-life.
Mouse studies strongly suggest that fine-tuning control
of FGF8 signaling through gene dosage and binding to
secreted inhibitors is essential for normal development.
The assessment of the impact of the p.R189H mutation
identified in this study on normal development awaits
the development of new mouse models in the future.
Recently a role forFGF8 in the etiologyofHPEhasbeen
proposed (15). However, because a cause-effect relation-
ship was not established and mutations were found in
heterozygosity, the possibility exists that mutations in
other genesmayunderlie the observed defects (digenicity).
Although loss-of-function homozygous mutations in
FGF8 have been identified or predicted previously in pa-
tients with normosmic idiopathic hypogonadotrophic hy-
pogonadism (16) and nonsyndromic cleft lip and palate,
respectively (31), our patient is the first with a recessive
form of HPE to be associated with an FGF8mutation; all
theother geneticmutations implicated in thedisorderhave
been transmitted in a heterozygous state with variable
penetrance. The lack of a phenotype in the heterozygous
parents is particularly intriguing, given that heterozygous
mutations in the gene have previously been associated
with Kallmann syndrome.
FIG. 3. Expression of FGF8 and FGFR1 during early human development. Expression of FGF8 (A)
and FGFR1 (B–E) during human embryonic CS 16 [37 d after fertilization (A and B) and CS 22 (C,
D, and E)]. Sagittal (A–D) and coronal sections (E) are shown. A, FGF8 transcripts are localized in
the commissural plate of the telencephalon (arrow in A), telencephalic/diencephalic border
(asterisk), and the prospective hypothalamus (arrowheads in A) but not in Rathke’s pouch (rp, blue
arrow), the primordium of the anterior pituitary gland. B–E, FGFR1 transcripts are widely detected
throughout the brain neuroepithelium (C and E) including the prospective hypothalamus (arrows
in B, D, and E), hindbrain (arrowheads in B), and the developing Rathke’s pouch (blue arrow in B,
rp in D and E). D, An enlarged image of the boxed area in C. Scale bar (B), 200 m; (C), 2 mm.
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Novel heterozygous mutation in FGF8 in a female
with SOD and Moebius syndrome
The patient with the heterozygous p.Q216E substitu-
tion, which lies in the same region as our homozygous
R189Hmutation,manifestedmidline defects including an
absent corpus callosum and hypoplastic optic nerves, re-
flecting a variant of SOD. A borderline GH response to
stimulation with a low-normal IGF-I was the only endo-
crine abnormality, although one cannot exclude the pos-
sibility of an evolving endocrinopathy, particularly with
reference to gonadotropin secretion.
An unusual finding in this patient was the presence of
Moebius syndrome, a rare congenital dysinnervation syn-
drome characterized by poorly developed abducens (VI)
FIG. 4. Mouse embryos carrying a Fgf8 hypomorphic allele exhibit pituitary and hypothalamic defects. In situ hybridization with specific markers
on pituitary (A–O) or hypothalamic (P–S) frontal histological sections. A–O, Terminal differentiation of somatotrophs [Gh expressing cells (A–C)],
corticotrophs and melanotrophs [Pomc1 expressing cells, D–F)], and thyrotropes and gonadotrophs [Cga expressing cells (G–I)] is unaffected in the
Fgf8 hypomorph (Fgf8loxPNeo/) embryos. However, the pituitary gland is smaller in the Fgf8 hypomorph embryos relative to Fgf8/ controls. Note
the absence of posterior lobe in one embryo (arrow in B, E, and H). Expression of Tsh was unaffected across the genotypes (J–L). However, a
proportion of Fgf8 hypomorphs exhibited lack of Lh-expressing cells (M–O). P–S, The endocrine hypothalamus is severely compromised in Fgf8
hypomorph embryos as revealed by in situ hybridization with AVP (P, P, Q, and Q) and OT (R, R, S, and S) antisense riboprobes. There is an
apparent reduction in numbers of AVP- and OT-expressing neurons in the SON, SCN, and PVN in the Fgf8 hymomorph embryos compared
with control littermates. P, Q, R, and S are magnified images of regions boxed in P, Q, R, and S of the same or an alternative section. T,
Quantification analysis of AVP-immunoreactive neurons demonstrates a significant reduction in numbers of these neurons in the SCN and PVN
nuclei of PN0 mice carrying specific combinations of Fgf8 alleles. Wt is Fgf8/, Het is Fgf8loxpNeo/, and Homo is Fgf8loxPNeo/. AL, Anterior lobe;
PL, posterior lobe;. Scale bars, 200 m. Data are mean  SD. **, P  0.002.
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and facial (VII) nerves (17). The condition has been asso-
ciatedwithKallmann syndrome in five cases (18),with the
only midline association reported recently in a child with
holoprosencephaly in which discontinuation of the preg-
nancy had been attemptedwithmisoprostol, an agent pre-
viously linkedwithMoebius syndrome (32, 33). Although
FGF8 has never previously been implicated in this disor-
der, its potential role is highlighted by its expression in the
facial primordia and eyes inmice and the presence of facial
skeletal defects in heterozygote Fgf8 zebrafish mutants,
which resemble several human craniofacial disorders (34,
35). Furthermore, tissue-specific ablation of Fgf8 was as-
sociated with abnormal neural crest survival and pattern-
ing, which gives rise to the cranial nerves and bone, car-
tilage, connective tissue, and skin pigmentation (36). In
agreement with this finding, the Fgf8loxPNeo/ embryos
analyzed in this study also presented craniofacial defects.
The unaffected mother of the patient was the heterozy-
gous carrier of the FGF8 mutation, suggesting variable
penetrance of the mutated allele, or possibly a digenic
cause of the disorder, both of which have been associated
with Kallmann syndrome due to FGF8 mutations. Cases
of the former are not unusual, with variable phenotypic-
presentations within a given family, making it difficult to
predict an expected phenotype based on the genotype
alone (37). Variations in environmental exposure may
also contribute to phenotypic variations (38). Alterna-
tively, more than one gene could contribute to the condi-
tion, particularly in the most severe form (39). Screening
for mutations in HESX1 and SHH, as well as other Kall-
mann syndrome-associated genes, failed to establish a di-
genic cause, although theremay be a contribution from an
as-yet-unknown gene, given that no genetic etiology has
been identified in the majority of patients with Kallmann
syndrome ormidline forebrain defects. The association of
Moebius syndrome with SOD in our patient, and with
Kallmann syndrome andHPE in other patients, implicates
an intrinsic link between these disorders in the form of
overlapping phenotypes; both our data and those pub-
lishedpreviouslypoint to associationswithmutatedFGF8
or related genes.
Fgf8/FGF8 is expressed in the developing
hypothalamus and implicated in normal
hypothalamo-pituitary development
Our expression analysis demonstrates that Fgf8/FGF8
is expressed in the telencephalonandventral diencephalon
(prospective hypothalamus) but not in Rathke’s pouch,
which is destined to form the anterior pituitary (39). Ex-
pression of FGFR1 colocalizes with FGF8 in the develop-
ing hypothalamus and is also found in Rathke’s pouch.
The similar localization of Fgf8/FGF8 expression in both
mice and humans as presented herein suggests that the
disrupted pituitary and hypothalamus in the Fgf8 hypo-
morphic mouse may parallel the endocrine deficits ob-
served in our patients. The patient with the homozygous
FGF8mutation presented a bulky anterior pituitary with
thepresenceof aposterior pituitarydespite the association
with diabetes insipidus, on MRI, and of note, the murine
hypomorphs showed marked variability in the size of the
anterior pituitary and the presence or otherwise of the
posterior pituitary. Additionally, the reduction in AVP in
themagnocellular SONand PVNof the hypomorphsmay
correlate with the diabetes insipidus observed in our pa-
tient, which is due to insufficient vasopressin signaling, a
hormone important formaintaining urinary salt/water re-
absorption (40). Furthermore,Fgf8hypomorphs also har-
bor defects in the parvicellular AVP neurons in the SCN,
suggesting that other hypothalamic functions such as cir-
cadian output may be dysregulated. Although not quan-
tified in this study, the reduction in OT staining in SON
and PVNnuclei is consistentwith recently published data,
which showedsignificantly reducedOTimmunoreactivity
in the same hypomorphic mice as used herein (26). Our
data suggest that the hypopituitary phenotypes observed
in our patients may be the result of reduced functional
FGF8 in the diencephalon, leading to deficiencies in the
neuroendocrine hypothalamus.
In conclusion, we report mutations in FGF8 that are
associated with complex midline phenotypes, including
the first autosomal recessive case of HPE and a potential
role in a patient with SOD and Moebius syndrome, the
genetic basis of the latter having remained elusive to date.
Analysis of our patients and murine hypomorphs, as well
as the conserved expression patterns of Fgf8/FGF8 and
Fgfr1/FGFR1 in mouse and human, suggests that FGF8
signaling is important for telencephalic andhypothalamo-
pituitary axis development and thatmutations in this gene
play a role in the pathogenesis of midline defects such as
HPE and SOD as well as Kallmann syndrome.
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